Showing 1-10 of about 10 articles.
Acepodia USA
ACE1702 demonstrates enhanced cytotoxicity against multiple HER2-expressing cell lines and activity under immunosuppressive conditions ACE1702 maintains activity following cryopreservationoNK cell...
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today...
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today...
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced...
Acepodia USA
• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients...
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, July 29, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) and...
Acepodia USA
JW therapeutics to receive exclusive licenses to develop and commercialize ACE1702 and ACE1655 in Mainland China, Hong Kong, and Macau Acepodia to receive upfront and milestone payments in addition...
Acepodia USA
Preclinical data demonstrate anti-tumor activity with ACE1702 in vitro and in vivo SAN FRANCISCO and TAIPEI, Taiwan, June 22, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing...
Acepodia USA
First clinical trial site for ACE1702 initiated, with clinical data expected in Q4 2020Investigational New Drug clearance expected for ACE1755 in Q1 2021 Pipeline expansion incorporating CAR...
Acepodia USA
SAN FRANCISCO and TAIPEI, Taiwan, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC™ (Antibody Cell-Conjugation) technology...
Showing 1-10 of about 10 articles.
